Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

According to this study, daily use of dutasteride 0.5 mg is the most effective treatment for male androgenic hair loss, while topical minoxidil serves as a viable alternative; combination treatments improve results, but more research is needed across various patient groups.

In this study, researchers found that dutasteride 0.5 mg/day is the most effective treatment for male androgenic alopecia, with topical minoxidil also being a viable option. Combination treatments improve outcomes, but further research is needed to evaluate efficacy across diverse patient groups.

Both 2.5 mg and 5 mg doses of oral minoxidil are effective for hair regrowth in men with hair loss.

Terbinafine 250 mg is the most effective treatment for fungal nail infections.

Taking 1 mg finasteride for a year reduces dihydrotestosterone levels in men with early hair loss, but doesn't change their metabolic state.

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

This study reported that spironolactone at 200 mg/day significantly improved facial hair growth in women with hirsutism and showed a sustained reduction in ovarian androgens over one year.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This study found that flutamide at 250 mg daily modestly improved hair thinning in premenopausal women with hyperandrogenic alopecia over one year, while cyproterone acetate and finasteride were not effective.

This study found that 2.5 mg/mL triamcinolone acetonide injections were as effective as higher doses for treating limited, patchy alopecia areata, while minimizing side effects like skin atrophy.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This review reports that 100 mg/day spironolactone improved hair growth more than placebo and was more effective in reducing hair growth than finasteride and low-dose cyproterone acetate, but its effectiveness for acne remains unclear due to small sample sizes.

This study found that finasteride (1 mg/day) appeared to reverse the shortening of the hair cycle in androgen sensitive sites but did not convert miniaturized hair into terminal hair.

This study found that spironolactone 100 mg daily did not demonstrate objective benefits in managing idiopathic hirsutism, as it increased hair shaft diameter without reducing serum androgen levels.

This study found that spironolactone at 200 mg/day effectively reduced facial hair growth in women with moderate to severe hirsutism, with improvements observed within two months and sustained over one year.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This study found that a 5-mg daily dose of transdermal testosterone cream in postmenopausal women restored testosterone levels to those typical of premenopausal women.

This study found that finasteride 1 mg daily decreased 5alpha-dihydrotestosterone levels and improved hair growth in younger men with androgenetic alopecia, with higher initial hormone levels predicting better response.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This study found that finasteride 1 mg per day improved hair growth and slowed hair loss in Japanese men with male pattern hair loss compared to lower doses and placebo.

This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.

This study found that administerating 10 mg/kg intramuscular fulvestrant did not stimulate hair regrowth in Pomeranian dogs with alopecia X, though higher doses may warrant further investigation.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

This study found that adding 10 mg/day of biotin to isotretinoin treatment for acne improved hair growth and maintained skin hydration, potentially reducing isotretinoin's mucocutaneous side effects.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This study found that two different 5 mg finasteride tablet formulations are bioequivalent in terms of the rate and extent of absorption in healthy volunteers.

This study found that 18 mg melatonin implants did not significantly prevent recurrence of canine flank alopecia compared to placebo in dogs, though the treatment was well-tolerated, with no evidence of improved efficacy.